Shares of Urovant Sciences Ltd (NASDAQ:UROV) have earned a consensus recommendation of “Buy” from the six research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $23.40.
UROV has been the subject of a number of research analyst reports. HC Wainwright initiated coverage on shares of Urovant Sciences in a research report on Monday, March 11th. They issued a “buy” rating and a $28.00 target price for the company. SunTrust Banks initiated coverage on shares of Urovant Sciences in a research report on Friday, March 15th. They issued a “buy” rating and a $24.00 target price for the company. Finally, Zacks Investment Research downgraded shares of Urovant Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, December 26th.
A number of large investors have recently bought and sold shares of the business. FMR LLC grew its position in Urovant Sciences by 11.1% in the 4th quarter. FMR LLC now owns 1,332,701 shares of the company’s stock worth $8,782,000 after purchasing an additional 132,701 shares during the period. Perceptive Advisors LLC grew its position in shares of Urovant Sciences by 35.2% during the 4th quarter. Perceptive Advisors LLC now owns 625,359 shares of the company’s stock valued at $3,915,000 after acquiring an additional 162,700 shares during the period. Sio Capital Management LLC bought a new stake in shares of Urovant Sciences during the 3rd quarter valued at $7,097,000. BlackRock Inc. bought a new stake in shares of Urovant Sciences during the 3rd quarter valued at $4,574,000. Finally, Sphera Funds Management LTD. grew its position in shares of Urovant Sciences by 30.5% during the 4th quarter. Sphera Funds Management LTD. now owns 214,030 shares of the company’s stock valued at $1,410,000 after acquiring an additional 50,000 shares during the period. 22.77% of the stock is owned by institutional investors and hedge funds.
Urovant Sciences (NASDAQ:UROV) last announced its quarterly earnings data on Wednesday, February 13th. The company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.22. Sell-side analysts expect that Urovant Sciences will post -3.96 earnings per share for the current fiscal year.
About Urovant Sciences
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Further Reading: Market Capitalization – What it Means for Investors
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.